newsfilter
← Latest News
GlobeNewswire·

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CGON
  • CG Oncology reported second-quarter 2026 financial results & provided business updates on August 6, 2026.
  • PIVOT-006 Phase 3 topline data for cretostimogene monotherapy in intermediate-risk NMIBC is anticipated in the near-term.
  • BLA completion for high-risk BCG-unresponsive NMIBC is expected in the fourth quarter of 2026.
  • BOND-003 Cohort C study results validating clinical evidence for cretostimogene were published in The Lancet Oncology.
  • The Delaware Superior Court denied ANI's post-trial motion, upholding the jury verdict that the royalty provision was properly severed while the rest of the agreement remains in force.
  • CORE-008 Cohort CX data was presented at the 2026 AUA Annual Meeting.
  • The company holds approximately $1.0 billion in cash, cash equivalents, & marketable securities, sufficient to fund operations through 2029.
  • R&D expenses increased to $54.7 million in Q2 2026 from $31.3 million in the prior year due to higher clinical trial & compensation costs.
  • G&A expenses rose to $29.0 million in Q2 2026 from $17.4 million in the prior year, driven by increased personnel-related expenses.
  • The company reported a net loss of $79.1 million ($0.90 per share) for Q2 2026, compared to a net loss of $41.4 million ($0.54 per share) in the prior year.
  • Total revenues for the three months ended June 30, 2026, were $1.157 million, up from zero in the same period of 2025.
  • Cretostimogene is an investigational oncolytic immunotherapy studied in over 600 NMIBC patients across two Phase 3 trials & a multi-cohort Phase 2 trial.